- Published at
- by investing.com
mixed
mixed
Germany stocks mixed at close of trade; DAX up 0.24% By Investing.com
Germany stocks mixed at close of trade; DAX up 0.24%
News for Formycon AG (0W4N.L)
- Published at
- by seekingalpha.com
neutralneutralTeva inks partnership with Klinge to launch Eylea biosimilar in Europe (NYSE:TEVA)
Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to Eylea in Europe.- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveTeva Pharmaceutical Expands Biosimilar Portfolio with Strategic Collaboration
Teva Pharmaceutical Industries Ltd (TEVA) announced on January 13, 2025, a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclu- Published at
- by gurufocus.com
positivepositiveFormycon AG (XTER:FYB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges
Revenue: Decrease compared to 2023, expected and within range.EBITDA: Decrease to minus EUR17.7 million, expected due to reduced revenues and increased R&D and- Published at
- by gurufocus.com
positivepositiveQ3 2024 Formycon AG Earnings Call Transcript
Nov 28, 2024 / 02:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Thank you very much for the kind introduction.- Published at
- by markets.businessinsider.com
positivepositiveEQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
EQS-News: Formycon AG / Key word(s): 9 Month figures/Conference Formycon invites to earnings call on the nine-month results ...- Published at
- by markets.businessinsider.com
mixedmixedEQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
EQS-News: Formycon AG / Key word(s): Statement/Regulatory Admission Formycon receives positive CHMP opinion for FYB203 (afli...- Published at
- by markets.businessinsider.com
positivepositiveEQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
EQS-News: Formycon AG / Key word(s): Regulatory Admission/IPO Formycon applies for admission to the Prime Standard of the Fr...- Published at
- by investing.com
positivepositiveFormycon announces positive FYB206 biosimilar study By Investing.com
Formycon announces positive FYB206 biosimilar study- Published at
- by gurufocus.com
positivepositiveFormycon AG (XTER:FYB) (H1 2024) Earnings Call Highlights: Strong Operational Performance Amidst Revenue Challenges
FYB201 Royalties: EUR3.8 million, tripling from EUR1.1 million in H1 2023.FYB202 Deferred Milestones: EUR11.3 million, down from EUR23.7 million in H1 2023.Dev- Published at
- by gurufocus.com
positivepositiveHalf Year 2024 Formycon AG Earnings Call Transcript
Aug 13, 2024 / 01:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Thank you very much and warm welcome from my s- Published at
- by investing.com
positivepositiveFresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz) By Investing.com
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)- Published at
- by marketscreener.com
positivepositiveFormycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon AG / Key word: AGM/EGM/Personnel Formycon invites to the Annual General Meeting on June 12, 2024 in Munich 07.05.2024 / 11:00 CET/CEST The issuer...- Published at
- by globenewswire.com
mixedmixedPlacental Growth Factors Market Growth 2023 along with Business Insights and Forecast to 2033
Here’s how Placental Growth Factors Help in Prediction, Diagnosis, and Treatment of Pre-eclampsia Conditions? FMI Predicts the Market to Surpass US$ 64.6...- Published at
- by prnewswire.com
mixedmixedBiosimilars Market Research Report 2023 - Global Forecast to 2028 - Patent Expiries of Blockbuster Biologics and Research into New Indications Presents Opportunities
/PRNewswire/ -- The "Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin,...- Published at
- by thestreet.com
mixedmixedWorldwide Biosimilars Industry To 2025 - By Type Of Biosimilar, Therapeutic Application And Region
DUBLIN, June 14, 2021 /PRNewswire/ -- The